Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors

for the Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalReview article

Abstract

The role of vitamin D in melanoma is still controversial. Although several Authors described a correlation between vitamin D deficiency and poor survival in metastatic melanoma patients, clinical trials exploring the effects of vitamin D supplementation in this clinical setting were mostly inconclusive. However, recent evidence suggests that vitamin D exerts both anti-proliferative effects on tumor cells and immune-modulating activities, that have been widely explored in auto-immune disorders. On the one hand, vitamin D has been shown to inhibit T-helper17 lymphocytes, notoriously involved in the pathogenesis of immune-related adverse events (iAEs) which complicate immune-checkpoint inhibitor (ICI) treatment. On the other hand, vitamin D up-regulates PDL-1 expression on both epithelial and immune cells, suggesting a synergic effect in combination with ICIs, for which further investigation is needed.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalCancer Treatment Reviews
Volume69
DOIs
Publication statusPublished - Sep 1 2018

Keywords

  • Immune check-point inhibitors
  • Immune related adverse events
  • Melanoma
  • PDL-1
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors'. Together they form a unique fingerprint.

  • Cite this